Mobile

A Phase 2 Trial of MLN8237, an Oral Aurora A Kinase Inhibitor, in Adult Patients with Acute Myelogenous Leukemia and High-Grade Myelodysplastic Syndrome

Mise à jour : Il y a 4 ans
Référence : EUCTR2008-006977-34

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To estimate antitumor activity of MLN8237 as measured by response rate in patients with AML and high-grade MDS

Critère d'inclusion

  • Acute myelogenous leukemia (AML) and high-grade myelodysplastic syndrome (MDS)

Liens